H.C. Wainwright analyst Robert Burns assumed coverage of Karyopharm (KPTI) with a Buy rating and $27 price target The firm believes the company’s investigation into maintenance therapy for the solid tumor indication is “risk-mitigated.” Karyopharmhas “several significant data catalysts” that could drive investor interest, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm Therapeutics Stockholders Approve Equity Plan Amendment
- Karyopharm’s Earnings Call: Clinical Gains Amid Financial Strains
- Karyopharm abstract selected for presentation at 2025 EHA meeting
- Karyopharm price target lowered to $33 from $43 at RBC Capital
- Karyopharm price target lowered to $42 from $54 at Baird